Zobrazeno 1 - 10
of 128
pro vyhledávání: '"J Dirk Iglehart"'
Autor:
Bose S Kochupurakkal, Zhigang C Wang, Tony Hua, Aedin C Culhane, Scott J Rodig, Koraljka Rajkovic-Molek, Jean-Bernard Lazaro, Andrea L Richardson, Debajit K Biswas, J Dirk Iglehart
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140243 (2015)
Both oncogenic and tumor-suppressor activities are attributed to the Nuclear Factor kappa B (NF-kB) pathway. Moreover, NF-kB may positively or negatively regulate proliferation. The molecular determinants of these opposing roles of NF-kB are unclear.
Externí odkaz:
https://doaj.org/article/e2c8ac55fb3a48a5adfcf77cafd2d682
Autor:
Matija Dreze, Anne S Calkins, Judit Gálicza, Daniel J Echelman, Mathew R Schnorenberg, Gillian L Fell, Shigenori Iwai, David E Fisher, David Szüts, J Dirk Iglehart, Jean-Bernard Lazaro
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85896 (2014)
Because cells are constantly subjected to DNA damaging insults, DNA repair pathways are critical for genome integrity [1]. DNA damage recognition protein complexes (DRCs) recognize DNA damage and initiate DNA repair. The DNA-Damage Binding protein 2
Externí odkaz:
https://doaj.org/article/75b1ffd2a6a74e609d2a41653e46bd91
Autor:
Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart, Zhigang C Wang
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80023 (2013)
BackgroundIncreased number of single nucleotide substitutions is seen in breast and ovarian cancer genomes carrying disease-associated mutations in BRCA1 or BRCA2. The significance of these genome-wide mutations is unknown. We hypothesize genome-wide
Externí odkaz:
https://doaj.org/article/af39aee1554b495da94db92c355a9275
Autor:
Rinath M Jeselsohn, Lillian Werner, Meredith M Regan, Aquila Fatima, Lauren Gilmore, Laura C Collins, Andrew H Beck, Shannon T Bailey, Housheng Hansen He, Gilles Buchwalter, Myles Brown, J Dirk Iglehart, Andrea Richardson, Steven E Come
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e64225 (2013)
Advancements in molecular biology have unveiled multiple breast cancer promoting pathways and potential therapeutic targets. Large randomized clinical trials remain the ultimate means of validating therapeutic efficacy, but they require large cohorts
Externí odkaz:
https://doaj.org/article/0167b02320db44619be2f68bca433504
Autor:
Bose S Kochupurakkal, J Dirk Iglehart
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68509 (2013)
Development of Nourseothricin N-acetyl transferase (NAT) as a selection marker for mammalian cells is described. Mammalian cells are acutely susceptible to Nourseothricin, similar to the widely used drug Puromycin, and NAT allows for quick and robust
Externí odkaz:
https://doaj.org/article/41f845453c834adc88c2b7ed6f716e50
Autor:
Thomas W Chittenden, Jane Pak, Renee Rubio, Hailing Cheng, Kristina Holton, Niall Prendergast, Vladimir Glinskii, Yi Cai, Aedin Culhane, Stefan Bentink, Mathew Schwede, Jessica C Mar, Eleanor A Howe, Martin Aryee, Razvan Sultana, Anthony A Lanahan, Jennifer M Taylor, Chris Holmes, William C Hahn, Jean J Zhao, J Dirk Iglehart, John Quackenbush
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e15581 (2010)
GIPC1 is a cytoplasmic scaffold protein that interacts with numerous receptor signaling complexes, and emerging evidence suggests that it plays a role in tumorigenesis. GIPC1 is highly expressed in a number of human malignancies, including breast, ov
Externí odkaz:
https://doaj.org/article/6d1b85371e1d4a2e868189e325035379
Autor:
Andrea L. Richardson, Zoltan Szallasi, Daniel P. Silver, Judy E. Garber, Paula D. Ryan, Nadine Tung, J. Dirk Iglehart, April Greene-Colozzi, Yang Li, Christian Bowman-Colin, Ruiyang Tian, Qiyuan Li, Aron C. Eklund, Ji-Young Kim, Zhigang C. Wang, Nicolai J. Birkbak
PDF file - 325K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a1a4b90234da8eca618384bc14c662f
https://doi.org/10.1158/2159-8290.22528647.v1
https://doi.org/10.1158/2159-8290.22528647.v1
Autor:
Debajit K. Biswas, J. Dirk. Iglehart, Myles Brown, Alexander Miron, Teresa Bowman, Kathleen M. Foley, Ruiyang Tian, Scott. J. Rodig, Gautam Maulik, Bose Kochupurakkal, Yoon J. Choi, Penelope L. Miron, Shannon T. Bailey
Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2-positive breast cancer, but resistance inevitably occurs. We previously found that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f36413cd5f35e3b13b71c7b9413ebc2
https://doi.org/10.1158/1541-7786.c.6539457
https://doi.org/10.1158/1541-7786.c.6539457
Autor:
Debajit K. Biswas, J. Dirk. Iglehart, Myles Brown, Alexander Miron, Teresa Bowman, Kathleen M. Foley, Ruiyang Tian, Scott. J. Rodig, Gautam Maulik, Bose Kochupurakkal, Yoon J. Choi, Penelope L. Miron, Shannon T. Bailey
PDF file - 78K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fbc4335ca11a30aa40bb5c5aaae5e9b
https://doi.org/10.1158/1541-7786.22509957.v1
https://doi.org/10.1158/1541-7786.22509957.v1
Autor:
Andrea L. Richardson, Zoltan Szallasi, Daniel P. Silver, Judy E. Garber, Paula D. Ryan, Nadine Tung, J. Dirk Iglehart, April Greene-Colozzi, Yang Li, Christian Bowman-Colin, Ruiyang Tian, Qiyuan Li, Aron C. Eklund, Ji-Young Kim, Zhigang C. Wang, Nicolai J. Birkbak
PDF file - 298K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e27886c1bd38c4ee21d2084fe6d107
https://doi.org/10.1158/2159-8290.22528644
https://doi.org/10.1158/2159-8290.22528644